Recent

% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • mynameissteve258 mynameissteve258 Aug 22, 2013 1:02 PM Flag

    Goldman maintains Sell rating on Incyte after Jakafi results LINK

    Seeking Alpha Market Currents
    Goldman maintains Sell rating on Incyte after Jakafi results

    "The Street is assigning value to Jakafi in other solid cancers (e.g., lung cancer), which we believe is premature given lack of data and limited visibility on subgroup criteria," Goldman's Navdeep Singh says, regarding the huge run up in shares of Incyte (INCY -4.5%) following the release of data from a Phase 2 pancreatic cancer study.
    Goldman maintains its Sell rating on the shares.
    Price target is $26, some 28% lower than Wednesday's close.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INCY
89.07+0.31(+0.35%)Sep 27 4:00 PMEDT